{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:36:44Z","timestamp":1794465404776,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-026-01275-1","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:36:45Z","timestamp":1770140205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of c-Abl inhibitor vodobatinib in subjects with early Parkinson\u2019s disease: a phase 2, randomized, double-blind, placebo-controlled study"],"prefix":"10.1038","volume":"12","author":[{"given":"Harini","family":"Sarva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hernandez-Vara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupam","family":"Borgohain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart A.","family":"Factor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Inamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Hames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Mergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Goldfine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Piccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu-Long","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orest","family":"Hurko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"1275_CR1","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","volume":"339","author":"AE Lang","year":"1998","unstructured":"Lang, A. E. & Lozano, A. M. Parkinson\u2019s disease. First two parts N. Engl. J. Med. 339, 1044\u20131053 (1998).","journal-title":"First two parts N. Engl. J. Med."},{"key":"1275_CR2","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1056\/NEJM199810153391607","volume":"339","author":"AE Lang","year":"1998","unstructured":"Lang, A. E. & Lozano, A. M. Parkinson\u2019s disease. Second two parts N. Engl. J. Med. 339, 1130\u20131143 (1998).","journal-title":"Second two parts N. Engl. J. Med."},{"key":"1275_CR3","doi-asserted-by":"publisher","first-page":"a024091","DOI":"10.1101\/cshperspect.a024091","volume":"8","author":"J Burr\u00e9","year":"2018","unstructured":"Burr\u00e9, J., Sharma, M. & S\u00fcdhof, T. C. Cell biology and pathophysiology of \u03b1-synuclein. Cold Spring Harb. Perspect. Med. 8, a024091 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1275_CR4","first-page":"879","volume":"152","author":"M Baba","year":"1998","unstructured":"Baba, M. et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879\u2013884 (1998).","journal-title":"Am. J. Pathol."},{"key":"1275_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","volume":"71","author":"MF Beal","year":"2014","unstructured":"Beal, M. F. et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 71, 543\u2013552 (2014).","journal-title":"JAMA Neurol."},{"key":"1275_CR6","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow, C. W. et al. A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N. Engl. J. Med. 361, 1268\u20131278 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1275_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R. & Foltynie, T. Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol. 20, 559\u2013572 (2021).","journal-title":"Lancet Neurol."},{"key":"1275_CR8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00702-023-02632-7","volume":"130","author":"C Buhmann","year":"2023","unstructured":"Buhmann, C., Magnus, T. & Choe, C. U. Blood neurofilament light chain in Parkinson\u2019s disease. J. Neural Transm. 130, 755\u2013762 (2023).","journal-title":"J. Neural Transm."},{"key":"1275_CR9","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/mds.28206","volume":"35","author":"B Mollenhauer","year":"2020","unstructured":"Mollenhauer, B. et al. Validation of serum neurofilament light chain as a biomarker of Parkinson\u2019s disease progression. Mov. Disord. 35, 1999\u20132008 (2020).","journal-title":"Mov. Disord."},{"key":"1275_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mds.28858","volume":"37","author":"MH Werner","year":"2022","unstructured":"Werner, M. H. & Olanow, C. W. Parkinson\u2019s disease modification through abl kinase inhibition: an opportunity. Mov. Disord. 37, 6\u201315 (2022).","journal-title":"Mov. Disord."},{"key":"1275_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fnagi.2016.00254","volume":"8","author":"D Lindholm","year":"2016","unstructured":"Lindholm, D. et al. c-Abl inhibitors enable insights into the pathophysiology and neuroprotection in Parkinson\u2019s disease. Front. Aging Neurosci. 8, 254 (2016).","journal-title":"Front. Aging Neurosci."},{"key":"1275_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/cells10020283","volume":"10","author":"DA Madsen","year":"2021","unstructured":"Madsen, D. A., Schmidt, S. I., Blaabjerg, M. & Meyer, M. Interaction between Parkin and \u03b1-synuclein in PARK2-mediated Parkinson\u2019s disease. Cells 10, 2 (2021).","journal-title":"Cells"},{"key":"1275_CR13","first-page":"589","volume":"7","author":"S Brahmachari","year":"2017","unstructured":"Brahmachari, S. et al. c-Abl and Parkinson\u2019s disease: mechanisms and therapeutic potential. J. Park. Dis. 7, 589\u2013601 (2017).","journal-title":"J. Park. Dis."},{"key":"1275_CR14","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1172\/JCI85456","volume":"126","author":"S Brahmachari","year":"2016","unstructured":"Brahmachari, S. et al. Activation of tyrosine kinase c-Abl contributes to \u03b1-synuclein-induced neurodegeneration. J. Clin. Investig. 126, 2970\u20132988 (2016).","journal-title":"J. Clin. Investig."},{"key":"1275_CR15","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","volume":"27","author":"S Lee","year":"2018","unstructured":"Lee, S. et al. The c-Abl inhibitor, radotinib HCl, is neuroprotective in a preclinical Parkinson\u2019s disease mouse model. Hum. Mol. Genet. 27, 2344\u20132356 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"1275_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep04874","volume":"4","author":"SS Karuppagounder","year":"2014","unstructured":"Karuppagounder, S. S. et al. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson\u2019s disease. Sci. Rep. 4, 4874 (2014).","journal-title":"Sci. Rep."},{"key":"1275_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fncel.2014.00050","volume":"8","author":"A Tanabe","year":"2014","unstructured":"Tanabe, A. et al. A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson\u2019s disease. Front. Cell. Neurosci. 8, 50 (2014).","journal-title":"Front. Cell. Neurosci."},{"key":"1275_CR18","doi-asserted-by":"crossref","unstructured":"Pagan F. et al. Nilotinib effects in parkinson\u2019s disease and dementia with Lewy bodies. J. Park. Dis. 6, 503\u201317 (2016).","DOI":"10.3233\/JPD-160867"},{"key":"1275_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","volume":"78","author":"T Simuni","year":"2021","unstructured":"Simuni, T. et al. Efficacy of nilotinib in patients with moderately advanced Parkinson\u2019s disease: a randomized clinical trial. JAMA Neurol. 78, 312\u2013320 (2021).","journal-title":"JAMA Neurol."},{"key":"1275_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","volume":"77","author":"FL Pagan","year":"2020","unstructured":"Pagan, F. L. et al. Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson\u2019s disease: a phase 2 randomized clinical trial. JAMA Neurol. 77, 309\u2013317 (2020).","journal-title":"JAMA Neurol."},{"key":"1275_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/mds.28389","volume":"36","author":"FL Pagan","year":"2021","unstructured":"Pagan, F. L. et al. Long-term safety and clinical effects of nilotinib in Parkinson\u2019s disease. Mov. Disord. 36, 740\u2013749 (2021).","journal-title":"Mov. Disord."},{"key":"1275_CR22","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/S2352-3026(24)00354-5","volume":"12","author":"JE Cortes","year":"2025","unstructured":"Cortes, J. E. et al. Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1\/2 trial. Lancet Haematol. 12, e201\u2013e213 (2025).","journal-title":"Lancet Haematol."},{"key":"1275_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.exphem.2019.08.007","volume":"77","author":"O Antelope","year":"2019","unstructured":"Antelope, O. et al. BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp. Hematol. 77, 36\u201340.e2 (2019).","journal-title":"Exp. Hematol."},{"key":"1275_CR24","unstructured":"A multiple dose study to evaluate the safety, tolerability and pharmacokinetics of K0706 in plasma and cerebrospinal fluid in healthy volunteers, NCT03445338 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03445338?term=NCT03445338&draw=2&rank=1."},{"key":"1275_CR25","unstructured":"Safety and tolerability study of K0706 in subjects with Parkinson\u2019s disease, NCT02970019 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02970019?term=NCT02970019&draw=2&rank=1. (Accessed 1 May 2022)."},{"key":"1275_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105281","volume":"108","author":"RR Walsh","year":"2023","unstructured":"Walsh, R. R. et al. Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson\u2019s disease. Park. Relat. Disord. 108, 105281 (2023).","journal-title":"Park. Relat. Disord."},{"key":"1275_CR27","unstructured":"The parkinson progression marker initiative (PPMI). Prog Neurobiol. 95, 629\u2013635 (2011)."},{"key":"1275_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano, G. et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N. Engl. J. Med. 387, 421\u2013432 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1275_CR29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang, A. E. et al. Trial of cinpanemab in early Parkinson\u2019s disease. N. Engl. J. Med. 387, 408\u2013420 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1275_CR30","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","volume":"387","author":"D Devos","year":"2022","unstructured":"Devos, D. et al. Trial of deferiprone in Parkinson\u2019s disease. N. Engl. J. Med. 387, 2045\u20132055 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1275_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","volume":"380","author":"CVM Verschuur","year":"2019","unstructured":"Verschuur, C. V. M. et al. Randomized delayed-start trial of levodopa in Parkinson\u2019s disease. N. Engl. J. Med. 380, 315\u2013324 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1275_CR32","unstructured":"AAN Issues Guideline for Treatment of Early Parkinson\u2019s Disease 2021 [Available from: https:\/\/www.aan.com\/PressRoom\/Home\/PressRelease\/4936#:~:text=AAN%20Issues%20Guideline%20for%20Treatment,of%20treatment%20for%20Parkinson\u2019s%20disease."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01275-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01275-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01275-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:23:37Z","timestamp":1773152617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01275-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1275"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01275-1","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HS acknowledges receiving grants or contracts from Prevail, BlueRock, Novo Nordisk, Neuroderm, Cerevance, MeiraGTX, Bukwang, Biogen, Genentech, Insightec, and UCB, and consulting fees from Neuroderm and Novo Nordisk. JF reports receiving grants or contracts from the Spanish Ministry of Health, consulting fees from AbbVie, Ever Pharma, and Orion Pharma, honoraria from AbbVie, Bial, Italfarmaco, and Stada, support for attending meetings and\/or travel from AbbVie and Italfarmaco, participated on a data safety monitoring committee for Bioartic, received medical equipment from Orion Pharma, and also stock ownership from Sense4care. RP reports receiving grants or contracts from Abbott, AbbVie, Amylyx, ASK Bio, Biogen, Bluerock (Bayer), Cerevance, Cerevel, EIP, Fasikl, Global Kinetics, Inhibikase, Intra-cellular Therapies (ITI), Jazz, Michael J Fox Foundation, Neurocrine, Neuroderm, Neuron 23, ONO, Parkinson\u2019s Foundation, Praxis, Roche, Sage, Saluda, Scion, Teva, Theravance, TrueBinding, UCB, and Ventus, consulting fees from Abbott, AbbVie, ACADIA, Amneal, Convatec, Fasikl, Genetech, Insightec, Jazz, Lundbeck, Merz, Mitsubishi Tanabe, Ono, PhotoPharmics, Sun Biopharma, and Supernus. SF reports receiving a grant from Rho Inc., participating on a data safety monitoring board for Biogen and Takeda, and participating in the Executive Committee Pan American section of the Movement Disorder Society.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}